Tontini Chiara, Radzikowska Urszula, Aranda Carlos J, Tynecka Marlena, Dolset María Isabel Delgado, Eljaszewicz Andrzej, Cornejo-García José Antonio, Villaseñor Alma, Ariza Adriana, Contreras Nuria, López-Rodríguez Juan C, Karaguzel Dilara, Lozano-Ojalvo Daniel, Castagnoli Riccardo, Eguiluz-Gracia Ibon, Sokolowska Milena, Mayorga Cristobalina, Hilger Christiane, Mortz Charlotte G, Pfaar Oliver, Barber Domingo, Escribese Maria M, Karaaslan Cagatay
Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
Allergy. 2025 Jul 2. doi: 10.1111/all.16638.
Omics have revolutionized our understanding of allergic diseases, with increasingly more studies adopting techniques like genomics, proteomics, and metabolomics over the years. Integrating high-dimensional omics data with clinical features can enable more precise disease classification and biomarker identification, leading to improved disease management and the development of novel therapies. However, translating these discoveries into clinical practice remains a challenge. In this European Academy of Allergy and Clinical Immunology (EAACI) Position Paper, the Task Force (TF) "The Use of Omics Sciences in Asthma and Allergy Clinical Practice" performed a broad review of recent papers where omics technologies were used in the context of clinical studies and provided a summary of relevant findings in the field of asthma, atopic dermatitis, allergic rhinitis, food allergy and drug hypersensitivity reactions. Particular attention was dedicated to studies investigating overlapping diseases/co-morbidities, revealing unique and shared signatures that could guide future therapeutic and research efforts. Furthermore, current hurdles in translating findings from bench to bedside were explained, and possible solutions were offered. With this position paper, the TF aims to assist researchers and clinicians by providing an overview of the investigations performed to date, highlighting gaps in research, limitations, and avenues for further exploration in clinical practice.
组学技术彻底改变了我们对过敏性疾病的理解，多年来越来越多的研究采用了基因组学、蛋白质组学和代谢组学等技术。将高维组学数据与临床特征相结合，可以实现更精确的疾病分类和生物标志物识别，从而改善疾病管理并推动新型疗法的开发。然而，将这些发现转化为临床实践仍然是一项挑战。在这份欧洲变态反应和临床免疫学会（EAACI）立场文件中，“组学科学在哮喘和变态反应临床实践中的应用”特别工作组（TF）广泛回顾了近期在临床研究背景下使用组学技术的论文，并总结了哮喘、特应性皮炎、过敏性鼻炎、食物过敏和药物过敏反应领域的相关发现。特别关注了调查重叠疾病/共病的研究，揭示了可指导未来治疗和研究工作的独特和共同特征。此外，还解释了目前将研究结果从实验室转化到临床所面临的障碍，并提出了可能的解决方案。通过这份立场文件，特别工作组旨在通过概述迄今为止所进行的研究，突出研究差距、局限性以及临床实践中进一步探索的途径，来帮助研究人员和临床医生。
